Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Kipimo cha Upenyezaji wa Seli za Caco-2× | Uundaji wa Kimodelia wa Madhara ya Dawa kwa Idadi ya Watu× | |
|---|---|---|
| Nyanja | Famakolojia | Famakolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 1989 | 1992 |
| Mwanzilishi≠ | Ingrid Hidalgo | Lewis Sheiner and Stephen Roush |
| Aina≠ | absorption screening | dose-response modeling |
| Chanzo asilia≠ | Hidalgo, I. J., Raub, T. J., & Borchardt, R. T. (1989). Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology, 96(3), 736-749. DOI ↗ | Dahlström, B., & Nyberg, L. (1993). Population pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics, 24(1), 45-57. link ↗ |
| Majina mbadala | Caco-2 assay, intestinal permeability, ADME screening | PopPD, population PD, hierarchical PD modeling |
| Zinazohusiana | 3 | 3 |
| Muhtasari≠ | The Caco-2 assay is an in vitro model system using human colon carcinoma cell monolayers to screen drug intestinal permeability. Developed by Hidalgo and colleagues in 1989, Caco-2 cells differentiate into an epithelial barrier resembling intestinal mucosa, enabling rapid assessment of drug absorption potential and identification of transporter-mediated transport. | Population pharmacodynamic (PopPD) modeling integrates pharmacokinetics with individual dose-response relationships across patient populations to characterize drug efficacy and tolerability. Pioneered by Lewis Sheiner and colleagues, PopPD accounts for inter-individual variability in drug effects and enables rational dose optimization and response prediction. |
| ScholarGateSeti ya data ↗ |
|
|